The first financial move after a serious diagnosis is almost always defensive. Cut what can be cut, protect the cash, stop anything that looks optional. Somewhere on that list of monthly drafts is a life insurance premium, and it is one of the easier lines to cross out.
That premium is attached to the only holding in the house that just went up.
Every Other Holding Reprices on News About the Asset
Earnings move a stock. Rate expectations move a bond. Comparable sales a few streets over move a house. In each case the news that changes the price is news about the thing you own.
A life insurance policy is the exception. Its market value moves on news about the owner, and it moves in the direction nobody wants to think about. Worse health, higher price.
Almost no one learns this, because almost no one ever sees a price. A policy arrives with two numbers on the annual statement, the death benefit and the cash surrender value, and neither of them is one.
What Actually Moves the Price
There is a secondary market for in-force life insurance. A policy owner sells the contract outright; the buyer inherits the premium obligation and, eventually, the claim.
Look at what that instrument is. A fixed future payment of uncertain timing, funded until then by an open-ended stream of premiums. It is a bond with an unknown maturity date and negative carry until it gets there. Price it and one input swamps the rest: how many years of premiums have to be paid before the payment shows up. That is the insured's life expectancy, and it comes out of medical underwriting, from people reading the actual records, not from anything printed in the contract.
Which is why the bands are so wide. Brokers and buyers price a standard sale, where the insured is a senior in ordinary health for their age, at roughly 10 to 25% of the policy's face value. Where a physician has certified 24 months or less, the same policy tends to price closer to 50 to 80%, and policies sold under a terminal diagnosis follow their own rules from there. Individual results vary. Some files come back with no bids at all.
Run that against a $500,000 policy. The standard band works out to $50,000 to $125,000. The certified band works out to $250,000 to $400,000. Same contract, same face amount, same carrier, same premium schedule. The variable that moved was a medical file.
The Number the Carrier Reports Cannot See Any of This
Cash surrender value is not a valuation. It is the exit price the contract itself produces, run off the policy's own terms and the premiums paid into it. Nothing in that calculation asks how the insured is doing, which is why the figure reads the same the week before a diagnosis and the week after.
Industry figures put it around 3 to 5% of face value on most permanent policies. On that $500,000 policy, call it $15,000 to $25,000, in hand within about two to four weeks. Real money, and fast. It is simply not a price, and it is the only number the owner is ever handed.
The carrier is under no obligation to mention that a market exists, and it has no commercial reason to. A surrender closes the file at the contractual figure. A lapse can close it at nothing at all, and every premium already collected stays collected. Life insurers are perfectly sound businesses, and this site covers a number of them as investments, but a reader who holds both the stock and the policy is sitting on both sides of that particular trade.
Getting to a Price Means Getting More Than One Bid
The market is real and it is thin. In 2025, 2,955 policies changed hands, according to the Life Insurance Settlement Association. In a market that small, where each buyer carries its own portfolio needs and its own reading of the medical file, the gap between one bid and several is not a rounding error.
That is what the brokered side of this market exists to do. Citizens Life Group is one of the shops working that way, taking a single case out to a group of institutional bidders so the number comes out of an auction rather than a negotiation.
The Liquidation That Usually Comes Out Untaxed
Where the cash comes from decides how much of it survives.
IRS Publication 525 states that certain amounts paid as accelerated death benefits under a life insurance contract or viatical settlement before the insured's death are excluded from income if the insured is terminally or chronically ill, and that those benefits are fully excludable where the insured has been certified by a physician as having an illness or physical condition that can reasonably be expected to result in death within 24 months from the date of the certification. Chronic-illness cases carry more conditions.
Set that beside the other ways a household raises the same cash. Selling an appreciated position realizes a gain. Drawing from a traditional IRA is ordinary income. Which account gets tapped first is an ordinary sequencing question right up until a policy with a certified diagnosis enters the list, at which point the order most planners default to stops being obviously right. None of this is tax advice, and the answer turns on facts a general article does not have, so the sequence is worth pricing with a tax professional rather than one leg at a time.
Where the Frame Breaks Down
Calling a diagnosis a repricing event is accurate and it is cold. Nobody living through one experiences it as portfolio news, and if you want a reason this market stays invisible, that is probably it. The people best positioned to use it are the people with the least appetite for hearing about it.
The mechanics narrow it further. Bidders screen on age and size, generally 65 and up on the insured and $100,000 and up on the face amount, and a healthy 66-year-old often draws no interest at all, which is the same rule running in reverse. Term coverage is sellable only while its conversion privilege is still open; once the term expires, that option is gone. A sale also ends the coverage, so a family genuinely counting on the death benefit is trading away the thing they were counting on, and arrangements that sell part of the policy and leave some benefit in place are worth asking about before a full sale. Proceeds can affect means-tested benefits such as Medicaid and SSI, which belongs in the decision rather than in a footnote.
The Bottom Line
A repricing event you decline to look at is still a repricing event. The policy carries a market value the week the diagnosis arrives and none at all the month after the coverage lapses for nonpayment. Finding out the number costs an application and some medical records. Not finding it out costs whatever the number was.
Comments
Log in or sign up to join the conversation.